Study Rationale

This Phase 3 trial targets patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy. While the combination of a BTK inhibitor and a BCL‑2 inhibitor has become the standard of care, ongoing discussions focus on tolerability and the durability of long‑term benefit. Consequently, evaluating the efficacy and safety of the novel fixed‑duration combination of Sonotroklox (BGB‑11417) and Janubrutinib (BGB‑3111) ("SZ") is essential.

Mechanism of Action

Sonotroklox is a BCL‑2 inhibitor, and Janubrutinib is a BTK inhibitor. BCL‑2 inhibition blocks the protein that prevents apoptosis, whereas BTK inhibition disrupts B‑cell receptor signaling. Co‑administration of the two agents for a predefined fixed period is expected to produce synergistic tumor cell death.

Comparator

The control arm consists of the established fixed‑duration regimen of Venetoclax plus Acalabrutinib ("AV"), which is widely used in the market. "AV" has demonstrated positive outcomes in multiple Phase 3 studies and is recognized as a standard therapy. If "SZ" shows superiority over "AV" in progression‑free survival (PFS) and overall survival (OS), it could broaden and differentiate treatment options.

Clinical Design

The study is randomized, double‑blind, and multi‑center. The primary endpoint is PFS. Patient enrollment began on January 22, 2026, with an anticipated primary completion date set for the end of 2029. This design enables simultaneous assessment of long‑term safety and treatment durability.

Market Impact

Should "SZ" demonstrate a statistically and clinically meaningful advantage versus the current "AV" regimen, it could establish a new standard in the BTK + BCL‑2 combination market. This may reshape existing partnership structures and licensing agreements, providing investors with a fresh growth catalyst.